Can Sanofi And GSK Catch Up In mRNA Vaccines?
Pfizer And Moderna Have Head Start
GSK and Sanofi have little chance of making a big impact in COVID-19 vaccines, but hope to establish themselves in the technology in key markets such as flu.
You may also be interested in...
The biopharma industry broke records again in 2021 with the amount of money raised for drug development. After a year of rapid growth, what will 2022 bring for market dynamics and R&D catalysts in biopharma?
VaxEquity’s founder dropped out of the race to develop a COVID-19 vaccine last year – but it and new partner AstraZeneca see potential not just in vaccines, but therapeutics too.
Gennova Biopharma’s mRNA ambitions are taking wing as its HDT Bio-partnered self-amplifying vaccine moves to Phase II. Notably, the company will have to prove superiority to AstraZeneca/Serum Institute’s Covishield in what appears to be the first comparative study for a COVID-19 vaccine candidate in India, Scrip learns.